Exosomal microRNAs as diagnostic biomarkers and therapeutic applications in neurodegenerative diseases

Neurol Res. 2023 Mar;45(3):191-199. doi: 10.1080/01616412.2022.2129768. Epub 2022 Oct 2.

Abstract

Originating from slow irreversible and progressive loss and dysfunction of neurons and synapses in the nervous system, neurodegenerative diseases (NDDs) affect millions of people worldwide. Common NDDs include Parkinson's disease, Alzheimer's disease multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis. Currently, no sensitive biomarkers are available to monitor the progression and treatment response of NDDs or to predict their prognosis. Exosomes (EXOs) are small bilipid layer-enclosed extracellular vesicles containing numerous biomolecules, including proteins, nucleic acids, and lipids. Recent evidence indicates that EXOs are pathogenic participants in the spread of neurodegenerative diseases, contributing to disease progression and spread. EXOs are also important tools for diagnosis and treatment. Recently, studies have proposed exosomal microRNAs (miRNAs) as the targets for therapies or biomarkers of NDDs. In this review, we outline the latest research on the roles of exosomal miRNAs in NDDs and their applications as potential diagnostic and therapeutic biomarkers, targets, and drugs for NDDs.

Keywords: Neurodegenerative disease; biomarker; drug delivery; exosomal miRNA; exosome.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / metabolism
  • Biomarkers / metabolism
  • Humans
  • Huntington Disease*
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • MicroRNAs* / therapeutic use
  • Neurodegenerative Diseases* / diagnosis
  • Neurodegenerative Diseases* / genetics
  • Neurodegenerative Diseases* / therapy

Substances

  • MicroRNAs
  • Biomarkers